Streetbeat News

ELEV

Elevation Oncology, Inc.

https://elevationoncology.com

Industry

Biotechnology

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Elevation Oncology (NASDAQ:ELEV) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 2:39 pm

Elevation Oncology plans to expand its Phase 1 trial to include two combination cohorts evaluating EO-3021 for advanced gastric or gastroesophageal junction cancer. The company expects to initiate dosing by the end of 2024, following clinical supply agreements with Eli Lilly and GSK.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 11:32 am

Piper Sandler has initiated coverage on Elevation Oncology (NASDAQ:ELEV) with an Overweight rating and a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 9:56 am

Stephens & Co. analyst Sudan Loganathan initiates coverage on Elevation Oncology (NASDAQ:ELEV) with an Overweight rating and a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:13 am

The article reports on the performance of health care stocks in Monday's after-market session, highlighting significant gainers and losers. Notably, Aesthetic Medical Intl, Harrow, and Vaxart experienced upward movements, attributed to recent earnings releases for some. Conversely, Augmedix, Akoya Biosciences, and Calidi Biotherapeutics saw notable declines, also influenced by their earnings reports.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 8:31 pm

Wedbush analyst Robert Driscoll reiterated an Outperform rating on Elevation Oncology (NASDAQ:ELEV) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 1:38 pm

In Thursday's intraday session, health care stocks saw significant movements. Emergent BioSolutions (EBS) led the gainers with a 98.4% increase following their Q1 earnings release. Other notable gainers include Nuwellis (NUWE), Sensei Biotherapeutics (SNSE), and Syra Health (SYRA). On the losing side, Accuray (ARAY) dropped 27.6% after their Q3 earnings, with Metagenomi (MGX) and Elevation Oncology (ELEV) also experiencing declines. The movements were attributed to recent earnings reports and market reactions.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 4:31 pm

Elevation Oncology's stock price declined following the announcement of disappointing Q1 GAAP EPS results.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 4:00 pm

Elevation Oncology announced that its cash, cash equivalents, and marketable securities totaling $104.1M as of March 31, 2024, along with $14.5M in net proceeds from its ATM facility after Q1 2024, will fund operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:26 pm

Elevation Oncology (NASDAQ:ELEV) reported a Q1 2024 GAAP EPS loss of $(0.23), missing the $(0.20) estimate by 15%. However, this represents a 68.06% improvement over the $(0.72) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:24 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.